CoChat

Pharmacodynamics of a Long-Acting Echinocandin, CD101, in a Neutropenic Invasive-Candidiasis Murine Model Using an Extended-Interval Dosing Design

Open access
Lepak, Alexander J., Zhao, Miao, VanScoy, Brian, Ambrose, Paul G., Andes, David R. · 2018 · Antimicrobial Agents and Chemotherapy
Cited by 63

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Echinocandins are important in the prevention and treatment of invasive candidiasis but limited by current dosing regimens that include daily intravenous administration. The novel echinocandin CD101 has a prolonged half-life of approximately 130 h in humans, making it possible to design once-weekly dosing strategies. The present study examined the pharmacodynamic activity of CD101 using the neutropenic invasive candidiasis mouse model against select Candida albicans ( n = 4), C. glabrata ( n = 3), and C. parapsilosis ( n = 3) strains. The CD101 MIC ranged from 0.03 to 1 mg/liter. Plasma pharmacokinetic measurements were performed using uninfected mice after intraperitoneal administration of 1, 4, 16, and 64 mg/kg. The elimination half-life was prolonged at 28 to 41 h. Neutropenic mice were infected with each strain by lateral tail vein injection, treated with a single dose of CD101, and monitored for 7 days, at which time the organism burden was enumerated from the kidneys. Dose-dependent activity was observed for each organism. The pharmacokinetic/pharmacodynamic (PK/PD) index of the area under the concentration-time curve over 24 h in the steady state divided by the MIC (AUC/MIC index) correlated well with efficacy ( R 2 , 0.74 to 0.93). The median stasis 24-h free-drug AUC/MIC targets were as follows: for C. albicans , 2.92; for C. glabrata , 0.07; and for C. parapsilosis , 2.61. The PK/PD targets for 1-log 10 kill endpoint were 2- to 4-fold higher. Interestingly, the aforementioned PK/PD targets of CD101 were numerically lower for all three species than those of other echinocandins. In summary, CD101 is a promising, novel echinocandin with advantageous pharmacokinetic properties and potent in vivo pharmacodynamic activity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/aac.02154-17

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 20

  1. 10.1093/cid/civ1194 · DOI · Paper page
  2. 10.1086/376906 · DOI · Paper page
  3. 10.1128/AAC.00051-14 · DOI
  4. 10.1016/j.idc.2015.10.003 · DOI
  5. 10.1016/j.jinf.2016.06.011 · DOI
  6. 10.1093/cid/ciu1128 · DOI · Paper page
  7. 10.1007/s10096-014-2287-4 · DOI
  8. 10.1128/AAC.02687-16 · DOI
  9. 10.1093/jac/dkw214 · DOI · Paper page
  10. 10.1016/j.diagmicrobio.2017.07.007 · DOI
  11. 10.1128/AAC.02045-16 · DOI · Paper page
  12. 10.1016/j.ijantimicag.2017.03.028 · DOI · Paper page
  13. 10.1128/AAC.01584-09 · DOI · Paper page
  14. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A3, 3rd ed. Clinical and Laboratory Standards Institute, Wayne, PA.
  15. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, DC.
  16. 10.1128/AAC.00507-06 · DOI · Paper page
  17. 10.1128/AAC.49.12.5058-5068.2005 · DOI · Paper page
  18. 10.1128/AAC.43.9.2148 · DOI · Paper page
  19. 10.1128/AAC.46.6.1857-1869.2002 · DOI · Paper page
  20. 10.1128/AAC.35.7.1321 · DOI · Paper page

Cited by

See all 63

Metadata

Authors
Lepak, A. J., Zhao, M., VanScoy, B., Ambrose, P. G., & Andes, D. R.
Venue
Antimicrobial Agents and Chemotherapy
Published
2018-02
Volume
62
Issue
2
ISSN
  • 0066-4804 (ISSN-L)
  • 1098-6596
OpenAlex
W2772135503
Cited by
63
References
10
FWCI
5.02
Type
journal article
Language
en
Open access
bronze
Licence
journals.asm.org/non-commercial-tdm-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.